Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brett Waverly

Podiatrist Maple Grove, MN Doctor of Podiatric Medicine

NPI 1902241268 CMS profile 1915018

7840 Vinewood Ln N, Maple Grove, MN 55369

Open in the dashboard

General payments

$7,863

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brett Waverly of Maple Grove, MN is reported in the CMS Open Payments database as having received $7,863 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,833 22
2024 General $1,341 20
2023 General $44 2
2022 General $23 1
2020 General $2,820 18
2019 General $802 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brett Waverly
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Brett Waverly were reported at $2,833. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Brett Waverly Podiatrist median Middle half National median
2019 $802 $196 $72–$601 $163
2020 $2,820 $118 $38–$335 $114
2021 $0 $169 $57–$573 $132
2022 $23 $220 $74–$782 $149
2023 $44 $208 $71–$635 $160
2024 $1,341 $237 $87–$681 $164
2025 $2,833 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $4,756 52 payments
  2. Arthrex, Inc. $2,324 10 payments
  3. Fortis Surgical, LLC $491 2 payments
  4. Foundation Medical, LLC $242 5 payments
  5. ERMI Inc. $26 1 payment
  6. Orthofix Medical, Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,516 61 payments
  2. Travel and Lodging $2,590 8 payments
  3. Education $1,757 2 payments
Products named General payments · program years 2019–2025
  1. ORTHOLOC 2 LAPIFUSE $1,135 9 payments
  2. ORTHOLOC 3DI $840 3 payments
  3. AUGMENT INJECTABLE $589 10 payments
  4. ALLOFIBER $453 4 payments
  5. ANCHORAGE $376 5 payments
  6. BIOLOX $215 5 payments
  7. STAR $190 3 payments
  8. ALLOMATRIX $185 2 payments
  9. CITREFIX $183 2 payments
  10. ACTISHIELD $173 2 payments
  11. Other $810 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

65

Median for Podiatry: 160

Drug cost

$315

Median for Podiatry: $2,368

Branded share of claims

27.7%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 15 $114
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 18 $102
Methylprednisolone Generic 14 $57
Meloxicam Generic 18 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$26,781

Of which drugs: $50

Medicare patients

244

Average age 72

Services billed

567

148 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 50%
Diabetes 22%
Depression 22%
Ischemic heart disease 20%
Chronic kidney disease 18%
Heart failure 15%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 60 $45
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 14 60 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record